Peregrine reports Cotara data

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) reported additional data from a Phase II trial in 41 glioblastoma multiforme (GBM) patients at first relapse showing that a single 25-hour interstitial infusion of Cotara led to an interim median overall survival of 38 weeks. Peregrine previously said expected survival for patients with GBM is typically 24 weeks from the time of disease recurrence. Additionally, 73%, 38% and 19% of patients were alive at 6, 12 and 24 months, respectively, and 2 patients have survived 3 years following treatment. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...